Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy.
Pavesi
Giovanni
G
Cattaneo
Luigi
L
Marbini
Adriana
A
Gemignani
Franco
F
Mancia
Domenico
D
D001369:Axons / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D001379:Azathioprine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods* / Q000706:statistics & numerical data*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D009416:Nerve Regeneration / Q000187:drug effects* / Q000276:immunology; D009431:Neural Conduction / Q000187:drug effects / Q000276:immunology; D010525:Peripheral Nerves / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D020127:Recovery of Function / Q000187:drug effects* / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D016898:Interferon-alpha; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone